Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
Provided By GlobeNewswire
Last update: Sep 24, 2024
Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) --
Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business update and reported its first half 2024 financial results.
Read more at globenewswire.com
